FDAnews
www.fdanews.com/articles/132261-merck-reports-initial-results-of-phase-iii-study-of-isentress

Merck Reports Initial Results of Phase III Study of Isentress

November 29, 2010
Merck Monday reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS (raltegravir) Tablets once daily in treatment-naive adult patients infected with HIV-1.
FreshNews